- Lefamulin met all primary FDA and EMA endpoints with a favorable tolerability profile - - Conference call and webcast today at 8:30 a.m. EDT to review results - DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 18, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage
Colin Broom, M.D. to serve as interim chief medical officer DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat
Expects top-line data from LEAP 1 CABP Phase 3 trial in September 2017 and from LEAP 2 CABP Phase 3 trial in the first quarter 2018 DUBLIN, Ireland , Aug. 07, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Aug. 02, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today
Further Strengthens Management Team of Industry Veterans to Support Commercialization of Potential New Antibiotic for Community-Acquired Bacterial Pneumonia DUBLIN, Ireland and KING OF PRUSSIA, Pa. , July 11, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical
DUBLIN, Ireland, June 26, 2017 – Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced the
DUBLIN, Ireland , June 26, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (" Nabriva Therapeutics ") today announced that it has successfully concluded its previously announced tender offer related to the exchange of common shares (" Nabriva AG Common Shares ") of Nabriva Therapeutics plc ("
VIENNA, Austria and KING OF PRUSSIA, Pa. , June 05, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class
Four abstracts demonstrate potential for lefamulin as a first-line, empiric treatment for patients with community-acquired bacterial pneumonia VIENNA, Austria and KING OF PRUSSIA, Pa. , June 02, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical
DUBLIN, Ireland , May 23, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (" Nabriva Ireland ") today commenced the previously announced tender offer related to the exchange of American depositary shares (" Nabriva AG ADSs ") and common shares (" Nabriva AG Common Shares ") of Nabriva
